You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pamiparib

Showing 1 - 25 of 28
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Cancer Trial in Hefei (Pamiparib, Surufatinib)

Recruiting
  • Ovarian Cancer
  • Hefei, Anhui, China
    Anhui Cancer Hospital
Dec 6, 2022

Ovarian Cancer Trial in Guangzhou (Pamiparib/Tamoxifen)

Not yet recruiting
  • Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Dec 30, 2022

Epithelial Ovarian Cancer Trial in Hangzhou (Pamiparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Pamiparib
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 4, 2022

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Platinum-Sensitive Biliary Tract Cancer Trial (Cisplatin, Gemcitabine, Oxaliplatin)

Withdrawn
  • Platinum-Sensitive Biliary Tract Cancer
  • (no location specified)
May 27, 2022

Neoadjuvant Therapy Trial in Nanjing (pamiparib, abiraterone, prednisone)

Recruiting
  • Neoadjuvant Therapy
  • pamiparib
  • +2 more
  • Nanjing, Jiangsu, China
  • +2 more
Jan 3, 2023

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Limited Stage Small Cell Lung Cancer Trial in Shanghai (Pamiparib)

Recruiting
  • Limited Stage Small Cell Lung Cancer
  • Pamiparib
  • Shanghai, Shanghai, China
  • +1 more
Jul 29, 2022

Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult Trial in Phoenix (Pamiparib, Olaparib, Radiation therapy)

Recruiting
  • Glioblastoma
  • +2 more
  • Pamiparib
  • +3 more
  • Phoenix, Arizona
    St. Joseph's Hospital and Medical Center
May 3, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Pamiparib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 7, 2022

Cancer Trial in Melbourne (Pamiparib, Tislelizumab)

Recruiting
  • Cancer
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Mar 3, 2022

Advanced Solid Tumors Trial in Bebington, Liverpool ([14C]-pamiparib)

Completed
Has Results
  • Advanced Solid Tumors
  • Bebington, Wirral, United Kingdom
  • +1 more
Aug 30, 2021

Clear Cell Papillary Renal Tumor, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma Trial in Los

Recruiting
  • Clear Cell Papillary Renal Neoplasm
  • +10 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 25, 2021

Ovarian Cancer, Carcinosarcoma Trial (Pamiparib)

Withdrawn
  • Ovarian Cancer
  • Carcinosarcoma
  • Pamiparib
  • (no location specified)
Aug 3, 2021

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Completed
  • Cancer
  • PARP inhibitor
  • Caen, Basse Normandie, France
    Alexandre Joachim
Sep 16, 2021

Pulmonary Toxicities Related to PARP Inhibitors (PulmonaRIB)

Recruiting
  • Cancer
  • olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib
  • Caen, Basse Normandie, France
    Alexandre Joachim
May 27, 2021

Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) Trial in Worldwide

Terminated
Has Results
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Homologous Recombination Deficiency (HRD)
  • Pamiparib
  • Athens, Georgia
  • +8 more
Oct 20, 2021

Ovarian Cancer Trial in Wuhan (Pamiparib, Bevacizumab, Tislelizumab)

Not yet recruiting
  • Ovarian Cancer
  • Pamiparib
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College, Huazhong University o
Oct 6, 2021

Advanced Malignancies Trial in Worldwide (Tislelizumab 200 mg, IV, Pamiparib 20, 40, 60 mg PO Twice Daily (BID), Pemetrexed 500

Enrolling by invitation
  • Advanced Malignancies
  • Tislelizumab 200 mg, IV
  • +4 more
  • Miami Beach, Florida
  • +50 more
Mar 4, 2022

Ovarian Cancer Trial in China (Pamiparib capsule, Placebo capsule)

Active, not recruiting
  • Ovarian Cancer
  • Pamiparib capsule
  • Placebo capsule
  • Hefei, Anhui, China
  • +27 more
Aug 18, 2022

Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer Trial in China (Pamiparib)

Active, not recruiting
  • Advanced High-grade Ovarian Cancer
  • Triple Negative Breast Cancer
  • Pamiparib
  • Hefei, Anhui, China
  • +25 more
Jun 16, 2021

Based on Quantitative Pharmacology in Patients With Pamipril

Not yet recruiting
  • Ovarian Cancer
    • (no location specified)
    Apr 28, 2023

    HER2-negative Breast Cancer Trial in China (BGB-290)

    Completed
    Has Results
    • HER2-negative Breast Cancer
    • Beijing, Beijing, China
    • +21 more
    Mar 28, 2022

    Solid Tumors Trial in Worldwide (Tislelizumab, Pamiparib)

    Completed
    Has Results
    • Solid Tumors
    • Tislelizumab
    • Pamiparib
    • Scottsdale, Arizona
    • +28 more
    Oct 27, 2021

    Advanced or Inoperable Gastric Cancer Trial in Worldwide (pamiparib, Placebo)

    Completed
    • Advanced or Inoperable Gastric Cancer
    • pamiparib
    • Placebo
    • Santa Rosa, California
    • +140 more
    Jan 10, 2023